<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.1038/s41419-024-06492-1</dc:identifier><dc:language>eng</dc:language><dc:creator>Bayona, Clara</dc:creator><dc:creator>Alza, Lía</dc:creator><dc:creator>Randelovic, Teodora</dc:creator><dc:creator>Sallán, Marta C.</dc:creator><dc:creator>Visa, Anna</dc:creator><dc:creator>Cantí, Carles</dc:creator><dc:creator>Ochoa, Ignacio</dc:creator><dc:creator>Oliván, Sara</dc:creator><dc:creator>Herreros, Judit</dc:creator><dc:title>Tetralol derivative NNC-55-0396 targets hypoxic cells in the glioblastoma microenvironment: an organ-on-chip approach</dc:title><dc:identifier>ART-2024-136959</dc:identifier><dc:description>Glioblastoma (GBM) is a highly malignant brain tumour characterised by limited treatment options and poor prognosis. The tumour microenvironment, particularly the central hypoxic region of the tumour, is known to play a pivotal role in GBM progression. Cells within this region adapt to hypoxia by stabilising transcription factor HIF1-α, which promotes cell proliferation, dedifferentiation and chemoresistance. In this study we sought to examine the effects of NNC-55-0396, a tetralol compound which overactivates the unfolded protein response inducing apoptosis, using the organ-on-chip technology. We identified an increased sensitivity of the hypoxic core of the chip to NNC, which correlates with decreasing levels of HIF1-α in vitro. Moreover, NNC blocks the macroautophagic process that is unleashed by hypoxia as revealed by increased levels of autophagosomal constituent LC3-II and autophagy chaperone p62/SQSTM1. The specific effects of NNC in the hypoxic microenvironment unveil additional anti-cancer abilities of this compound and further support investigations on its use in combined therapies against GBM.</dc:description><dc:date>2024</dc:date><dc:source>http://zaguan.unizar.es/record/131585</dc:source><dc:doi>10.1038/s41419-024-06492-1</dc:doi><dc:identifier>http://zaguan.unizar.es/record/131585</dc:identifier><dc:identifier>oai:zaguan.unizar.es:131585</dc:identifier><dc:relation>info:eu-repo/grantAgreement/EC/H2020/829010/EU/Advanced and versatile PRInting platform for the next generation of active Microfluidic dEvices/PRIME</dc:relation><dc:relation>This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 829010-PRIME</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MINECO/DIN2020-011544</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MINECO/RTI2018-094739-B-I00</dc:relation><dc:identifier.citation>CELL DEATH &amp; DISEASE 15, 2 (2024), 127 [8 pp.]</dc:identifier.citation><dc:rights>by</dc:rights><dc:rights>https://creativecommons.org/licenses/by/4.0/deed.es</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>